- Home
- IIIV vs LRMR Comparison
IIIV vs LRMR Comparison
Compare IIIV & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IIIV | LRMR |
|---|---|---|
| Founded | 2012 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.0M | 455.8M |
| IPO Year | 2018 | 2014 |
Fundamental Metrics
Financial Performance| Metric | IIIV | LRMR |
|---|---|---|
| Price | $15.88 | $3.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $33.20 | $16.50 |
| AVG Volume (30 Days) | 488.7K | ★ 908.7K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.24 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.05 | N/A |
| Revenue Next Year | $8.07 | $1,816.14 |
| P/E Ratio | $69.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.57 | $2.72 |
| 52 Week High | $33.97 | $6.42 |
Technical Indicators
Market Signals| Indicator | IIIV | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 35.10 | 46.59 |
| Support Level | $15.59 | $3.57 |
| Resistance Level | $17.12 | $4.21 |
| Average True Range (ATR) | 0.67 | 0.17 |
| MACD | 0.10 | -0.05 |
| Stochastic Oscillator | 12.67 | 29.03 |
Price Performance
Historical ComparisonAbout IIIV i3 Verticals Inc.
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.